HPV vaccination of immunocompromised hosts

dc.contributor.authorGarland, Suzanne M.
dc.contributor.authorBrotherton, J. M. L.
dc.contributor.authorMoscicki, Anna-Barbara
dc.contributor.authorKaufmann, A. M.
dc.contributor.authorStanley, Margaret
dc.contributor.authorBhatla, N.
dc.contributor.authorSankaranarayanan, Rengaswamy
dc.contributor.authorSanjosé Llongueras, Silvia de
dc.contributor.authorPalefsky, Joel
dc.date.accessioned2018-07-27T12:01:22Z
dc.date.available2018-07-27T12:01:22Z
dc.date.issued2017-12-01
dc.date.updated2018-07-24T11:53:24Z
dc.description.abstractIt is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.
dc.format.extent4 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid29179867
dc.identifier.urihttps://hdl.handle.net/2445/124030
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1016/j.pvr.2017.06.002
dc.relation.ispartofPapillomavirus Research, 2017, vol. 4, p. 35-38
dc.relation.urihttp://dx.doi.org/10.1016/j.pvr.2017.06.002
dc.rightscc by-nc-nd (c) Garland et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationVacuna del papil·lomavirus
dc.subject.otherPapillomavirus vaccines
dc.titleHPV vaccination of immunocompromised hosts
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
GarlandSM.pdf
Mida:
237.86 KB
Format:
Adobe Portable Document Format